Novel Treatments for Neurodegenerative Conditions

NeuroBo Pharmaceuticals is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease.

Our first product candidate, NB-01, is targeting neuropathic pain with a first indication in PDN. Phase 3 studies are planned and powered for efficacy and safety.

  • PDN affects 8.4M people worldwide representing global drug sales of $3.05B (2018, GlobalData)

  • Diabetes and cancer are amongst the leading causes of neuropathic pain

  • Symptoms range from dull and tingling to debilitating pain; limiting mobility, negatively impacting sleep, and hindering glycemic control (Ormseth et al. 2011)

  • Current treatments show 30% reduction of pain in 40% of patients

    • Only three approved therapies for PDN with high rates of adverse events

    • When these fail, even in combination, physicians often turn to off-label use of opioids

NB-02, our lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s Disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth).

  • Alzheimer’s disease affects 10.6M people globally (2016, Global Data)

  • Approved treatments focus on symptomatic management and largely on acetyl cholinesterase (AChE) inhibition

  • 650+ drug trials underway targeting Tau inhibition, amyloid plaque inhibition, and combinations with AChE inhibition

  • >20 diseases that result from tau protein aggregation in the brain; progressive supranuclear palsy (PSP) is a key focus

  • No current approved therapies for patients with tauopathies